153 related articles for article (PubMed ID: 35998008)
1. R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 9.
Simpson A; Ramagopalan SV
J Comp Eff Res; 2022 Nov; 11(16):1147-1149. PubMed ID: 35998008
[TBL] [Abstract][Full Text] [Related]
2. R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 10.
Simpson A; Ramagopalan SV
J Comp Eff Res; 2023 Jan; 12(1):e220194. PubMed ID: 36453665
[TBL] [Abstract][Full Text] [Related]
3. R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 6.
Simpson A; Ramagopalan SV
J Comp Eff Res; 2022 May; 11(7):473-475. PubMed ID: 35261285
[TBL] [Abstract][Full Text] [Related]
4. R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 8.
Simpson A; Ramagopalan SV
J Comp Eff Res; 2022 Sep; 11(13):915-917. PubMed ID: 35703134
[TBL] [Abstract][Full Text] [Related]
5. R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 7.
Simpson A; Ramagopalan SV
J Comp Eff Res; 2022 Jul; 11(10):699-701. PubMed ID: 35506497
[TBL] [Abstract][Full Text] [Related]
6. R WE ready for reimbursement? A round up of developments in real-world evidence relating to HTA: part 5.
Simpson A; Ramagopalan SV
J Comp Eff Res; 2022 Mar; 11(4):213-215. PubMed ID: 34989244
[TBL] [Abstract][Full Text] [Related]
7. R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 4.
Simpson A; Ramagopalan SV
J Comp Eff Res; 2022 Jan; 11(1):11-12. PubMed ID: 34702048
[TBL] [Abstract][Full Text] [Related]
8. R WE ready for reimbursement? A round up of developments in RWE relating to health technology assessment: part 2.
Simpson A; Ramagopalan SV
J Comp Eff Res; 2021 Sep; 10(13):957-959. PubMed ID: 34184540
[TBL] [Abstract][Full Text] [Related]
9. R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 14.
Bray BD; Ramagopalan SV
J Comp Eff Res; 2024 Jan; 13(1):e230189. PubMed ID: 38179957
[TBL] [Abstract][Full Text] [Related]
10. R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment.
Simpson A; Ramagopalan SV
J Comp Eff Res; 2021 Jul; 10(10):797-799. PubMed ID: 33955236
[TBL] [Abstract][Full Text] [Related]
11. R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 15.
Castanon A; Bray BD; Ramagopalan SV
J Comp Eff Res; 2024 May; 13(5):e240033. PubMed ID: 38546012
[TBL] [Abstract][Full Text] [Related]
12. R WE ready for reimbursement? A round up of developments in real-world evidence relating to HTA: part 3.
Simpson A; Ramagopalan SV
J Comp Eff Res; 2021 Nov; 10(16):1175-1176. PubMed ID: 34412538
[TBL] [Abstract][Full Text] [Related]
13. R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 11.
Bray B; Ramagopalan SV
J Comp Eff Res; 2023 May; 12(5):e230008. PubMed ID: 37052075
[TBL] [Abstract][Full Text] [Related]
14. R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 13.
Bray BD; Ramagopalan SV
J Comp Eff Res; 2023 Nov; 12(11):e230141. PubMed ID: 37712636
[TBL] [Abstract][Full Text] [Related]
15. Challenges in the development and reimbursement of personalized medicine-payer and manufacturer perspectives and implications for health economics and outcomes research: a report of the ISPOR personalized medicine special interest group.
Faulkner E; Annemans L; Garrison L; Helfand M; Holtorf AP; Hornberger J; Hughes D; Li T; Malone D; Payne K; Siebert U; Towse A; Veenstra D; Watkins J;
Value Health; 2012 Dec; 15(8):1162-71. PubMed ID: 23244820
[TBL] [Abstract][Full Text] [Related]
16. The ISPOR Good Practices for Quality Improvement of Cost-Effectiveness Research Task Force Report.
McGhan WF; Al M; Doshi JA; Kamae I; Marx SE; Rindress D
Value Health; 2009; 12(8):1086-99. PubMed ID: 19744291
[TBL] [Abstract][Full Text] [Related]
17. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Annual Meeting (May 17-20, 2021 - Virtual Meeting).
Kibble A
Drugs Today (Barc); 2021 Aug; 57(8):519-525. PubMed ID: 34405209
[TBL] [Abstract][Full Text] [Related]
18. Use of Real-World Evidence in US Payer Coverage Decision-Making for Next-Generation Sequencing-Based Tests: Challenges, Opportunities, and Potential Solutions.
Deverka PA; Douglas MP; Phillips KA
Value Health; 2020 May; 23(5):540-550. PubMed ID: 32389218
[TBL] [Abstract][Full Text] [Related]
19. Improving Transparency to Build Trust in Real-World Secondary Data Studies for Hypothesis Testing-Why, What, and How: Recommendations and a Road Map from the Real-World Evidence Transparency Initiative.
Orsini LS; Berger M; Crown W; Daniel G; Eichler HG; Goettsch W; Graff J; Guerino J; Jonsson P; Lederer NM; Monz B; Mullins CD; Schneeweiss S; Brunt DV; Wang SV; Willke RJ
Value Health; 2020 Sep; 23(9):1128-1136. PubMed ID: 32940229
[TBL] [Abstract][Full Text] [Related]
20. Real-world data for health technology assessment for reimbursement decisions in Asia: current landscape and a way forward.
Lou J; Kc S; Toh KY; Dabak S; Adler A; Ahn J; Bayani DBS; Chan K; Choiphel D; Chua B; Genuino AJ; Guerrero AM; Kearney B; Lin LW; Liu Y; Nakamura R; Pearce F; Prinja S; Pwu RF; Shafie AA; Sui B; Suwantika A; Teerawattananon Y; Tunis S; Wu HM; Zalcberg J; Zhao K; Isaranuwatchai W; Wee HL
Int J Technol Assess Health Care; 2020 Oct; 36(5):474-480. PubMed ID: 32928330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
